

Susan D Mathias

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3742313/publications.pdf>

Version: 2024-02-01

29
papers

1,159
citations

394286

19
h-index

501076

28
g-index

29
all docs

29
docs citations

29
times ranked

1273
citing authors

#	ARTICLE	IF	CITATIONS
1	<sc>WISH</sc>: A wish list for immune thrombocytopenia quality of life indicators becomes reality. <i>American Journal of Hematology</i> , 2021, 96, 172-173.	2.0	0
2	Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands. <i>Frontiers in Endocrinology</i> , 2021, 12, 627711.	1.5	18
3	Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider. <i>Pituitary</i> , 2020, 23, 140-148.	1.6	23
4	Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. <i>BMC Endocrine Disorders</i> , 2020, 20, 117.	0.9	22
5	An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies. <i>Pituitary</i> , 2020, 23, 347-358.	1.6	20
6	Development of a novel patient-reported measure for acromegaly: the Acro-TSQ. <i>Pituitary</i> , 2019, 22, 581-593.	1.6	14
7	Validity and responsiveness of the Urticaria Activity and Impact Measure. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 641-647.	0.5	5
8	Development of the Systemic Lupus Erythematosus Steroid Questionnaire (SSQ): a novel patient-reported outcome tool to assess the impact of oral steroid treatment. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 43.	1.0	18
9	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Romiplostim on Health-Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1232-1237.	0.8	38
10	The minimal important difference for measures of urticaria disease activity: Updated findings. <i>Allergy and Asthma Proceedings</i> , 2015, 36, 394-398.	1.0	21
11	Effect of Romiplostim on Health-Related Quality of Life in Children with Immune Thrombocytopenia and Associated Burden in Their Parents: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study. <i>Blood</i> , 2015, 126, 37-37.	0.6	2
12	Validation of the Patient Perception of Intensity of Urgency Scale in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. <i>Value in Health</i> , 2014, 17, 823-829.	0.1	9
13	Measurement properties of the Flu-Like Symptom Index from the Hepatitis Physical Symptom Severity Diary. <i>Quality of Life Research</i> , 2014, 23, 1489-1496.	1.5	1
14	Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 603-609.	1.1	30
15	Pain outcomes in patients with advanced breast cancer and bone metastases. <i>Cancer</i> , 2013, 119, 832-838.	2.0	126
16	Adaptation and validation of the Urticaria Patient Daily Diary for adolescents. <i>Allergy and Asthma Proceedings</i> , 2012, 33, 186-190.	1.0	13
17	Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 108, 20-24.	0.5	97
18	The burden of immune thrombocytopenia in adults: Evaluation of the thrombopoietin receptor agonist romiplostim. <i>Journal of Medical Economics</i> , 2012, 15, 956-976.	1.0	9

#	ARTICLE	IF	CITATIONS
19	Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). <i>Pediatric Blood and Cancer</i> , 2012, 58, 395-398.	0.8	41
20	Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. <i>American Journal of Hematology</i> , 2012, 87, 558-561.	2.0	68
21	Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). <i>Value in Health</i> , 2011, 14, 90-96.	0.1	27
22	Estimating Minimally Important Differences for the Worst Pain Rating of the Brief Pain Inventory—Short Form. <i>The Journal of Supportive Oncology</i> , 2011, 9, 72-78.	2.3	67
23	Development of a daily diary for patients with chronic idiopathic urticaria. <i>Annals of Allergy, Asthma and Immunology</i> , 2010, 105, 142-148.	0.5	59
24	Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences. <i>Current Medical Research and Opinion</i> , 2009, 25, 375-383.	0.9	24
25	Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. <i>British Journal of Haematology</i> , 2009, 144, 409-415.	1.2	150
26	Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. <i>Health and Quality of Life Outcomes</i> , 2008, 6, 13.	1.0	86
27	Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. <i>Current Medical Research and Opinion</i> , 2008, 24, 2767-2776.	0.9	79
28	A disease-specific measure of health-related quality of life in adults with chronic Immune Thrombocytopenic Purpura: Psychometric testing in an open-label clinical trial. <i>Clinical Therapeutics</i> , 2007, 29, 950-962.	1.1	38
29	A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: Its development and validation. <i>Health and Quality of Life Outcomes</i> , 2007, 5, 11.	1.0	54